CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Rituximab 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01584388
NCT01584388Phase 2Completed
CompareCT.gov

Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial

Massachusetts General Hospital·interventional·Posted Apr 25, 2012·Updated Jul 2, 2017

In Brief

A Phase 2 clinical trial evaluating Rituximab for Retroperitoneal Fibrosis and 3 related conditions. Completed, enrolled 30 participants.

Detailed Summary

The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis, Pseudotumor
Countries--
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2012
Enrollment StartApr 1, 2012
Primary CompletionJan 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.2 years ago

Interventions

Rituximabdrug

Rituximab 1000 mg IV times two doses, separated by approximately 15 days.